A new model using platelet indices to predict liver fibrosis in patients with chronic hepatitis B infection

dc.authorid0000-0001-9154-844X
dc.authorid0000-0001-9091-6087
dc.authorid0000-0002-8130-676X
dc.contributor.authorCeylan, Bahadir
dc.contributor.authorMete, Bilgul
dc.contributor.authorFincanci, Muzaffer
dc.contributor.authorAslan, Turan
dc.contributor.authorAkkoyunlu, Yasemin
dc.contributor.authorOzgunes, Nail
dc.contributor.authorColak, Onur
dc.date.accessioned2025-05-10T19:54:42Z
dc.date.issued2013
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstractWe aimed to investigate whether mean platelet volume (MPV) and platelet distribution width (PDW) are variables determining the severity of liver fibrosis in patients with chronic HBV infection. Patients were divided into two groups with fibrosis scores of 0-2 and 3-6 (according to Ishac scoring system). Whether MPV and PDW were independent variables determining the severity of liver fibrosis score or not was investigated by comparing these groups. Of the 111 cases, 74 (66.7 %) were male (mean age 37.7 +/- 11.6 years). Twenty-two of the cases (19.8 %) were HBeAg-positive. Fibrosis scores of 42 cases (37.8 %) were a parts per thousand yenaEuro parts per thousand 3 and the remaining 69 cases had fibrosis scores < 3 (62.2 %). Independent variables determining the severity of fibrosis score were low levels of albumin and mean platelet volume, and high levels of prothrombin time and PDW (Odds ratio (95 % confidence interval) and p values were 0.105 (0.018-0.605) and 0.012 for albumin, 0.402 (0.234-0.692) and 0.001 for mean platelet volume, 1.529 (1.183-1.975) and 0.001 for PDW, and 0.924 (0.875-0.976) and 0.005 for prothrombin time, respectively). The sensitivity, specificity, positive predictive value and negative predictive value of regression model that is established using above mentioned parameters were 88.1, 75.3, 68.5, and 91.7 %, respectively (AUC = 0.886, p = 0.0001). MPV and PDW are independent variables determining the severity of liver fibrosis, and the regression model that is established using these parameters along with other markers, may give more information about the severity of liver fibrosis.
dc.description.sponsorshipNovartis Pharmaceutical Company; Merck Pharmaceutical Company
dc.description.sponsorship(1) The presented data belong to Realist Observational Study. Realist Observational study is supported financially by Novartis Pharmaceutical Company. (2) Payment for English translation of the article was made by Merck Pharmaceutical Company.
dc.identifier.doi10.1007/s00508-013-0394-3
dc.identifier.endpage460
dc.identifier.issn0043-5325
dc.identifier.issn1613-7671
dc.identifier.issue15-16
dc.identifier.pmid23860694
dc.identifier.scopusqualityQ1
dc.identifier.startpage453
dc.identifier.urihttps://doi.org/10.1007/s00508-013-0394-3
dc.identifier.urihttps://hdl.handle.net/20.500.14730/13132
dc.identifier.volume125
dc.identifier.wosWOS:000323670700005
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer Wien
dc.relation.ispartofWiener Klinische Wochenschrift
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.subjectHepatitis B virus
dc.subjectLiver fibrosis
dc.subjectBlood platelets
dc.titleA new model using platelet indices to predict liver fibrosis in patients with chronic hepatitis B infection
dc.typeArticle

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
13132
Boyut:
855.03 KB
Biçim:
Adobe Portable Document Format